500-Patient study aims to unlock secrets of brain bleeding disease
NCT ID NCT04204642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting medical data and brain scans from 500 people with cerebral amyloid angiopathy (CAA), a condition that causes bleeding in the brain and memory problems in older adults. Researchers want to better understand how the disease progresses and find markers that could improve diagnosis. No new treatments are being tested; the goal is to gather knowledge that could guide future care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve how doctors diagnose and track cerebral amyloid angiopathy, and point toward future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any therapy, and results may take years to influence patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2020
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Sporadic and familial CAA patients
- Ages
-
55 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All consecutive patients ≥55 years (with the exception of genetic cases), referred to the participating centres, with a diagnosis of possible probable and definite symptomatic or asymptomatic CAA, defined according to the modified Boston neuroradiological criteria, who had undergone at least one brain MRI (mandatory requirement for inclusion of the patient in the study) will be recruited. Exclusion Criteria: * evidence of other causes of cerebral hemorrhage (brain tumors, arteriovenous malformations, aneurysms, cavernous angiomas), contraindications to brain MRI, pregnancy and breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cerebral amyloid angiopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UOC Neurologia 5
RECRUITINGMilan, Milano, 20133, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can olive oil and walnuts shield the brain from stroke and memory loss?
- Brain scan study reveals hidden differences in two common blood vessel diseases
- Your digital twin could help prevent another stroke
- Scientists hunt for biomarkers to predict brain vessel disease
- Eye injection could spot hidden brain bleeding risk
- Brain scan clues could help tell two blood vessel diseases apart